Total Payments
$121,724
2024 Payments
$29,700
Companies
29
Transactions
314
Medicare Patients
1,366
Medicare Billing
$277,641
Payment Breakdown by Category
Other$83,525 (68.6%)
Consulting$19,055 (15.7%)
Travel$12,008 (9.9%)
Food & Beverage$6,868 (5.6%)
Education$268.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,525 | 26 | 68.6% |
| Consulting Fee | $19,055 | 8 | 15.7% |
| Travel and Lodging | $12,008 | 52 | 9.9% |
| Food and Beverage | $6,868 | 223 | 5.6% |
| Education | $268.00 | 5 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $99,778 | 168 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,938 | 28 | $0 (2024) |
| Mylan Specialty L.P. | $4,424 | 23 | $0 (2024) |
| Genentech USA, Inc. | $2,848 | 8 | $0 (2023) |
| AstraZeneca UK Limited | $1,395 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $684.88 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $468.81 | 6 | $0 (2022) |
| La Jolla Pharmaceutical Company | $211.42 | 4 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $113.77 | 1 | $0 (2018) |
| GENZYME CORPORATION | $104.06 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,700 | 70 | GlaxoSmithKline, LLC. ($27,460) |
| 2023 | $69,686 | 92 | GlaxoSmithKline, LLC. ($69,096) |
| 2022 | $588.30 | 27 | GlaxoSmithKline, LLC. ($124.53) |
| 2021 | $5,757 | 30 | Genentech USA, Inc. ($2,710) |
| 2020 | $338.68 | 19 | GlaxoSmithKline, LLC. ($108.84) |
| 2019 | $2,524 | 25 | GlaxoSmithKline, LLC. ($2,254) |
| 2018 | $4,678 | 28 | Mylan Specialty L.P. ($3,755) |
| 2017 | $8,451 | 23 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,799) |
All Payment Transactions
314 individual payment records from CMS Open Payments — Page 2 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/15/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Immunology | ||||||
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $72.71 | General |
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $41.64 | General |
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $40.25 | General |
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $18.41 | General |
| 07/11/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $270.07 | General |
| 07/11/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $98.59 | General |
| 07/11/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $57.26 | General |
| 06/25/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.48 | General |
| Category: HFCWO | ||||||
| 06/13/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Oncology | ||||||
| 06/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: RESPIRATORY | ||||||
| 06/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Immunology | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Respiratory | ||||||
| 05/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Immunology | ||||||
| 05/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $124.73 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 05/21/2024 | GlaxoSmithKline, LLC. | — | Education | In-kind items and services | $57.00 | General |
| 05/20/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $42.50 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 05/15/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $588.97 | General |
| 05/15/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $31.02 | General |
| 05/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 05/08/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $18.52 | General |
| 05/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Respiratory | ||||||
| 05/01/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.54 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 04/18/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $9.45 | General |
| Category: HFCWO | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 221 | 325 | $141,723 | $41,732 |
| 2022 | 11 | 338 | 530 | $243,763 | $64,712 |
| 2021 | 11 | 402 | 661 | $319,316 | $83,862 |
| 2020 | 11 | 405 | 672 | $330,242 | $87,335 |
Total Patients
1,366
Total Services
2,188
Medicare Billing
$277,641
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 17 | 17 | $561.00 | $146.30 | 26.1% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 17 | 17 | $561.00 | $108.58 | 19.4% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 13 | 13 | $1,287 | $101.12 | 7.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 145 | 349 | $241,857 | $59,601 | 24.6% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2020 | 43 | 69 | $23,909 | $6,032 | 25.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 38 | 51 | $16,830 | $4,097 | 24.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 35 | 39 | $12,548 | $3,945 | 31.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 37 | 45 | $6,683 | $3,704 | 55.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $8,580 | $3,199 | 37.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 40 | $8,910 | $3,171 | 35.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $6,113 | $1,927 | 31.5% |
| 31500 | Emergent insertion of breathing tube into windpipe cartilage using an endoscope | Facility | 2020 | 11 | 12 | $3,690 | $1,382 | 37.4% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2020 | 17 | 17 | $561.00 | $158.72 | 28.3% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 17 | 17 | $561.00 | $117.64 | 21.0% |
About Dr. Douglas Mapel, MD
Dr. Douglas Mapel, MD is a Pulmonary Disease healthcare provider based in Prescott, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497730451.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Mapel, MD has received a total of $121,724 in payments from pharmaceutical and medical device companies, with $29,700 received in 2024. These payments were reported across 314 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($83,525).
As a Medicare-enrolled provider, Mapel has provided services to 1,366 Medicare beneficiaries, totaling 2,188 services with total Medicare billing of $277,641. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Internal Medicine, Critical Care Medicine
- Location Prescott, AZ
- Active Since 12/13/2005
- Last Updated 10/10/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1497730451
Products in Payments
- AREXVY (Drug) $93,823
- Yupelri (Drug) $3,898
- Xolair (Biological) $2,784
- STIOLTO RESPIMAT (Drug) $2,718
- YUPELRI (Drug) $525.34
- TRELEGY ELLIPTA (Drug) $512.18
- NUCALA (Biological) $477.86
- FEVIPIPRANT (Drug) $404.84
- ANORO (Drug) $314.62
- FASENRA (Drug) $230.64
- GIAPREZA (Drug) $211.42
- OFEV (Drug) $179.68
- DUPIXENT (Biological) $154.73
- TEZSPIRE (Biological) $137.07
- SPIRIVA (Drug) $128.02
- BREZTRI (Drug) $114.35
- GLASSIA (Biological) $109.31
- FASENRA (Biological) $106.58
- FLOWTRIEVER CATHETER, S (Device) $100.24
- XOLAIR (Biological) $63.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.